Nextvisit AI
AI clinical documentation platform specializing in behavioral health workflows for psychiatrists and therapists.
Website: https://ryanyannelli.com/projects/nextvisit-ai/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | Nextvisit AI |
| Tagline | AI clinical documentation platform specializing in behavioral health workflows for psychiatrists and therapists. |
| Headquarters | New York, US [Access Newswire, May 2026] |
| Founded | 2021 [Access Newswire, May 2026] |
| Stage | Pre-Seed [Startuply.vc, May 2026] |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2), Ryan Yannelli and Dr. Faisal Rafiq [ryanyannelli.com, Unknown] [Access Newswire, May 2026] |
| Funding Label | Pre-seed [Startuply.vc, May 2026] |
| Total Disclosed | ~$200,000 [Startuply.vc, May 2026] |
Links
Publicly reported
- Website: https://nextvisit.ai
- LinkedIn: https://www.linkedin.com/in/faisal-rafiq-md/
- Other: https://ryanyannelli.com/projects/nextvisit-ai/
Summary and Signal
PUBLIC Nextvisit AI builds AI clinical documentation software for behavioral health, and it is worth watching because the company is trying to sell a category that has shown broad provider demand while narrowing its wedge to psychiatrists, therapists, and mental health practices rather than general medical settings [Access Newswire, May 2026] [Digital Journal, December 2025]. The company was founded in 2021 in New York by Ryan Yannelli and Dr. Faisal Rafiq, with the public record pointing to a pairing of product engineering and practicing clinical expertise, a combination that fits the documentation problem it is targeting [Access Newswire, May 2026] [ryanyannelli.com] [LinkedIn].
The product listens to patient visits and drafts structured notes such as SOAP notes and intake documentation, with company materials also claiming support for coding, eligibility, and claims workflows plus integrations with Osmind, SimplePractice, and Kalix [ryanyannelli.com] [USA Today, 2026] [nextvisit.ai]. The differentiation case rests less on model novelty than on workflow specificity: public descriptions consistently frame Nextvisit around behavioral-health terminology and practice patterns, which is a credible positioning choice in a crowded ambient documentation market [Digital Journal, December 2025] [The News-Press, 2026].
On team, Yannelli is publicly identified as co-founder and CTO, while Rafiq is identified as co-founder and CEO and described as a practicing psychiatrist [ryanyannelli.com] [Access Newswire, May 2026] [LinkedIn]. That does not by itself establish enterprise go-to-market depth, but it does suggest the company has direct domain input at the product-definition layer, which matters in specialties where note structure, risk language, and follow-up workflows are clinically sensitive [Access Newswire, May 2026].
Capitalization remains early. Startuply reported a $200,000 pre-seed in May 2026 led by LAUNCH Fund, and Nextvisit also graduated from Jason Calacanis's LAUNCH Accelerator; both points are relevant signals, though the disclosed funding amount is lightly corroborated and should be treated conservatively [Startuply.vc, May 2026] [Access Newswire, May 2026]. The business model is SaaS, and founder-reported February 2026 metrics cited on This Week in Startups were 68 paying customers, $9,000 MRR, 311 users, $189 CAC, and $1,700 LTV, figures that are directionally useful but still company-supplied rather than independently verified [This Week in Startups episode, February 2026].
Over the next 12 to 18 months, the key question is whether Nextvisit can turn an apparently clear niche wedge into durable distribution and deeper workflow ownership. Investors should watch for independent evidence of retention, larger practice adoption, and whether integrations and newer product surfaces such as Nextvisit Go or telehealth-related features translate into a broader system of record position rather than a single-point note generator [nextvisit.ai] [Nextvisit news page, August 2026].
No independent source found -- This section relies materially on company-controlled sources, founder-reported operating metrics, and a lightly corroborated funding report, with only partial support from independent or semi-independent public coverage.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Pre-seed, total disclosed about $200,000 [Startuply.vc, May 2026] |
Company Overview
PUBLIC
The public record on Nextvisit AI is thin, but the basic company shape is clear enough to frame the diligence. Nextvisit AI describes itself as a behavioral-health clinical documentation company founded in 2021 and based in New York, with Ryan Yannelli and Dr. Faisal Rafiq identified as co-founders across company-linked materials and Crunchbase profiles [Crunchbase] [ryanyannelli.com] [ryanyannelli.com/about/].
From there, the chronology remains early. Company-linked materials present Nextvisit as an AI documentation platform focused on psychiatrists, therapists, and behavioral-health practices, while Crunchbase lists the business under the Nextvisit name and associates Ryan Yannelli with the company in a CTO role [ryanyannelli.com/projects/nextvisit-ai/] [Crunchbase]. No state filing or other public corporate record was provided in the sourced materials for this section, so the legal entity naming convention and formation details are not established here.
One source, partially checked -- Confirmed in part by Crunchbase and company website materials, with key company identity details corroborated but legal entity specifics not supported by a state filing in the provided sources.
The Product and the Stack
Public record plus analysis
The product is narrow by design, which is usually the right place to start in clinical workflow software. Nextvisit AI describes itself as an AI clinical-documentation platform for behavioral health that listens to patient visits and drafts structured notes, including SOAP notes and intake documentation, for psychiatrists, therapists, and behavioral-health practices [ryanyannelli.com, Unknown] [USA Today, 2026] [The News-Press, 2026]. That specialization matters because the company is not presenting as a general medical scribe; its own materials and press coverage consistently frame the wedge as mental-health terminology and workflow fit [ryanyannelli.com, Unknown] [Digital Journal, December 2025].
The public product surface extends beyond note generation, at least at the level of company claims. Nextvisit says the platform also supports coding, eligibility, and claims workflows downstream of the visit note [ryanyannelli.com, Unknown]. On its website, the company also advertises direct integrations with Osmind, SimplePractice, and Kalix, and describes Nextvisit Go as a separate note workspace for non-prescribing providers such as therapists and counselors [nextvisit.ai, retrieved 2026]. Those integration and workflow claims are commercially relevant if they hold up in live deployments, because behavioral-health practices often run fragmented systems and buy for workflow reduction rather than transcription alone.
The clearest public evidence of ongoing product development is an August 27, 2026 release note that added aged unsigned notes, a "Last time" function, a cross-titration advisor, Talk to Aria, and a telehealth beta request flow [nextvisit.ai, August 2026]. Even so, most of the technical detail remains company-supplied rather than independently demonstrated, and one third-party description from SoftwareWorld appears broader than the rest of the record, framing the product as general note-taking across meetings and events rather than a clinical workflow tool [SoftwareWorld, August 2026]. On balance, the public evidence supports a behavioral-health documentation product with some workflow adjacency, but not yet a deeply verified picture of architecture, model performance, or deployment depth.
No independent source found -- This section relies primarily on company-controlled product pages and website materials, with partial corroboration from press coverage.
The Market They Are Entering
PUBLIC
The market matters because ambient clinical documentation has moved from a physician-efficiency tool to a workflow decision, and behavioral health sits in a part of care delivery where documentation burden, reimbursement complexity, and provider burnout are all visible constraints on growth [Digital Journal, December 2025] [USA Today, 2026].
The evidence on market size is thin, so the right approach is to separate what is founder-reported from what is externally observable. Nextvisit itself cited a $2 billion total addressable market in a February 2026 founder interview, but that figure is company-reported and not tied to a named third-party methodology in the available record [This Week in Startups episode, February 2026]. Publicly supported market definition is clearer than public sizing: the company targets psychiatrists, therapists, and behavioral-health practices with AI-generated SOAP notes, intake documentation, and adjacent revenue-cycle tasks such as coding, eligibility, and claims support [Access Newswire, May 2026] [ryanyannelli.com]. That places the business at the intersection of behavioral-health software, medical transcription and scribing, and practice workflow automation rather than in a broad horizontal note-taking category [Access Newswire, May 2026] [USA Today, 2026].
Demand drivers are easier to substantiate than TAM. The most consistent theme across the available coverage is specialization. Nextvisit and its founders repeatedly frame mental-health terminology, psychiatric visits, and therapist workflows as distinct from general medical documentation, suggesting that category demand is being shaped by dissatisfaction with general-purpose medical scribes in this setting [Digital Journal, December 2025] [USA Today, 2026] [The News-Press, 2026]. A second tailwind is workflow adjacency. The product is described not only as a note generator but as software that can feed coding, eligibility, and claims processes, which matters because behavioral-health providers often operate in smaller practice settings where one software decision can affect both clinician time and administrative throughput [ryanyannelli.com] [Access Newswire, May 2026].
The adjacent and substitute markets are broad enough to matter for positioning. On one side, Nextvisit competes with general AI medical scribe platforms that can expand into psychiatry and therapy over time [Digital Journal, December 2025]. On the other, parts of the product sit close to electronic health record integrations and practice-management workflows, especially where the company cites integrations with Osmind, SimplePractice, and Kalix on its own site [nextvisit.ai, retrieved 2026]. Some public descriptions also place the software nearer to general transcription and note-taking, particularly the SoftwareWorld characterization tied to meetings and lectures, but that framing appears less precise than the healthcare-specific product descriptions and should be treated cautiously [SoftwareWorld, August 2026] [Access Newswire, May 2026].
Regulatory and macro forces are present in implication, even if the source set does not give a clean policy map. The company is selling into clinical documentation, which is a regulated workflow by definition, and its public materials emphasize accuracy, structured notes, and integration into existing practice systems rather than a fully autonomous clinical decision layer [USA Today, 2026] [ryanyannelli.com]. Macro conditions also favor automation that can preserve clinician capacity without adding headcount, especially in fragmented outpatient settings. What the public record does not yet establish is whether adoption is being pulled primarily by compliance needs, labor scarcity, reimbursement pressure, or competitive feature parity among behavioral-health platforms. That distinction will matter for market durability, but it is not resolved by the available sources [This Week in Startups episode, February 2026] [Access Newswire, May 2026].
| Sizing claim | Figure | Scope | Source quality |
|---|---|---|---|
| Total addressable market | $2 billion | Founder-stated TAM for Nextvisit | Company-reported in interview |
The table is narrow because only one explicit market-sizing figure appears in the public record. That is a useful signal of founder ambition, but not enough to underwrite a market model without external category data or a clearer bottoms-up buyer count.
No independent source found -- Market sizing in this section relies materially on a founder-reported TAM figure, while the broader market characterization is supported mainly by company statements and republished coverage [This Week in Startups episode, February 2026] [Access Newswire, May 2026] [USA Today, 2026].
The Competitive Field
Competitive map
MIXED Nextvisit AI is positioning itself against broad medical scribe vendors by narrowing the product surface to behavioral health, where psychiatric and therapy documentation has its own vocabulary, workflow, and reimbursement logic [ryanyannelli.com, Unknown] [Digital Journal, December 2025] [Access Newswire, May 2026].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Nextvisit AI | AI clinical documentation platform for behavioral health, aimed at psychiatrists, therapists, and behavioral-health practices | Pre-seed, reported $200,000 | Specialization in mental-health workflows; reported integrations with Osmind, SimplePractice, and Kalix; separate "Nextvisit Go" workspace for non-prescribing providers | [Startuply.vc, May 2026] [ryanyannelli.com, Unknown] [nextvisit.ai, retrieved 2026] |
| Abridge Inc | Named competitor in ambient clinical documentation | Named competitor only | Publicly identified in the research set as a comparator, but no further source-grounded detail was provided here | [Structured facts] |
| Tandem Health | Named competitor in clinical documentation | Named competitor only | Publicly identified in the research set as a comparator, but no further source-grounded detail was provided here | [Structured facts] |
| Lyrebird Health | Named competitor in clinical documentation | Named competitor only | Publicly identified in the research set as a comparator, but no further source-grounded detail was provided here | [Structured facts] |
The table is thin on peer detail because the underlying research names competitors but does not provide source-grounded funding, customer, or product specifics for those companies. That matters analytically. It means the cleanest public comparison is not feature-for-feature, but category-for-category: behavioral-health specialist versus broader documentation tools and existing practice workflows.
The segment map breaks three ways. First are specialist behavioral-health tools, where Nextvisit is trying to sit, pairing note generation with coding, eligibility, and claims support for psychiatry and therapy workflows [ryanyannelli.com, Unknown]. Third are adjacent substitutes: existing EHR-native documentation habits, human scribes, and manual note-taking inside practice systems such as Osmind, SimplePractice, and Kalix, all of which remain relevant because Nextvisit's own public materials emphasize integrations with those systems rather than replacement of the full workflow stack [nextvisit.ai, retrieved 2026].
Nextvisit's edge today appears narrow but real. The strongest public evidence is not scale, because the reported 68 paying customers and $9,000 MRR in February 2026 are founder-reported and lightly corroborated at best [This Week in Startups episode, February 2026] [Startuply.vc, May 2026]. The stronger point is founder-market fit: Dr. Faisal Rafiq is identified as a practicing psychiatrist, and the company repeatedly frames the product around behavioral-health terminology and documentation patterns rather than general medical transcription [Access Newswire, May 2026] [Digital Journal, December 2025]. That kind of domain focus can matter early, especially if it improves note quality for psychiatric intake and SOAP workflows. It is also perishable. Larger vendors can copy templates and terminology support faster than a small company can build distribution, unless the specialization compounds into proprietary usage data, entrenched integrations, or a recognized brand inside independent practices.
The main exposure is channel control and category breadth. Nextvisit's public footprint suggests it plugs into existing systems used by behavioral-health providers, but there is no public evidence here that it owns the EHR, payer relationship, or enterprise procurement channel [nextvisit.ai, retrieved 2026]. If a named rival such as Abridge can sell a broader ambient documentation product through health-system or platform-level relationships, a specialist like Nextvisit could be boxed into smaller practices or narrower use cases. The same is true at the lower end of the market, where providers may accept lighter functionality if documentation is bundled inside software they already use. In that setting, Nextvisit is competing not only with specialist AI vendors, but with the inertia of current workflow.
The most plausible 18-month scenario is a sorting between focused specialists and distribution-led platforms. Nextvisit is the likely winner if behavioral-health providers continue to prefer tools built around psychiatric language, therapist workflows, and practice-management integrations over one-size-fits-all scribes [ryanyannelli.com, Unknown] [nextvisit.ai, retrieved 2026]. A named loser in that scenario could be any generalist entrant that lacks behavioral-health depth, though the current source pack does not support singling out one by evidence. In that case, Nextvisit is the most exposed, particularly if its public traction remains concentrated in founder-led SMB adoption rather than institutional contracts [This Week in Startups episode, February 2026].
Thinly sourced -- This section relies on named public sources for Nextvisit's positioning and product scope, but competitor-specific details in the research set are sparse and partly limited to structured-facts naming rather than independently corroborated peer reporting.
Opportunity
PUBLIC
The prize here is not another ambient scribe, but a workflow system that could become the default operating layer for independent and mid-market behavioral-health clinicians if Nextvisit turns a narrow specialty wedge into durable software distribution [Access Newswire, May 2026] [Digital Journal, December 2025] [USA Today, 2026].
The largest plausible outcome is straightforward: Nextvisit becomes the specialist documentation and reimbursement stack for behavioral health, starting with note generation and moving into adjacent admin work that already sits in the product narrative. The evidence for reachability is early, but it is not abstract. Public materials consistently position the product around psychiatrists, therapists, and behavioral-health practices rather than general medicine, and they describe a product that drafts SOAP notes and intake documentation while also touching coding, eligibility, and claims workflows [ryanyannelli.com] [USA Today, 2026] [The News-Press, 2026]. That matters because behavioral health has both domain-specific language and fragmented practice operations, which can favor a specialist vendor over a horizontal scribe if the workflow fit is meaningfully better. The company also reported 68 paying customers and $9,000 in monthly recurring revenue in February 2026, modest by venture standards but enough to show that buyers will pay for this wedge if the product reduces documentation burden [This Week in Startups episode, February 2026] [Startuply.vc, May 2026].
The upside paths are not identical, and each depends on a different catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Behavioral-health system of record companion | Nextvisit becomes the preferred documentation layer attached to existing practice software for therapists and psychiatrists | Deeper integrations with behavioral-health tools already named by the company, including Osmind, SimplePractice, and Kalix [nextvisit.ai, retrieved 2026] | The product is already presented as specialized for behavioral health rather than general-purpose transcription, and the company has publicly claimed integrations with practice software used by target clinicians [ryanyannelli.com] [nextvisit.ai, retrieved 2026] |
| Multi-product expansion across provider types | The company uses its core scribe to launch adjacent products for separate clinical roles, raising revenue per account | Continued rollout of products such as Nextvisit Go for non-prescribing providers and feature expansion such as telehealth beta requests and note-management tools [nextvisit.ai, retrieved 2026] [nextvisit.ai, August 2026] | Public product pages already show segmentation by provider type and an active release cadence, which suggests the platform can broaden inside the same customer base before moving upmarket [nextvisit.ai, retrieved 2026] [nextvisit.ai, August 2026] |
| Accelerator-led distribution into a fragmented SMB market | Nextvisit converts founder-led traction into a repeatable go-to-market motion for small practices across North America | LAUNCH Accelerator exposure, founder media appearances, and continued low-cost acquisition if reported efficiency holds [Access Newswire, May 2026] [This Week in Startups episode, February 2026] | The company has already gone through LAUNCH and publicly reported a CAC of $189 alongside 68 paying customers, which, if directionally true, implies an SMB product that can be sold without heavy field-sales infrastructure [This Week in Startups episode, February 2026] [Startuply.vc, May 2026] |
The compounding mechanism would come from depth, not breadth. If one practice adopts note generation first, then activates coding, eligibility, claims support, and role-specific workflows, the switching cost shifts from a single writing tool to a system woven into daily clinical and billing operations [ryanyannelli.com] [nextvisit.ai, retrieved 2026]. That can improve retention, widen average contract value, and create a product feedback loop in which specialty-specific terminology, templates, and workflow edge cases make the software more useful for the next cohort of behavioral-health users. The public evidence is still company-led, but there are early signs of this layering already: named integrations, a separate workspace for non-prescribing providers, and ongoing feature releases around unsigned notes, medication-related assistance, and telehealth requests [nextvisit.ai, retrieved 2026] [nextvisit.ai, August 2026].
The size of the win is easiest to frame against what the company itself says it is pursuing and what the category has already attracted. Nextvisit cited a $2 billion total addressable market in a February 2026 founder interview, which should be treated as a company-reported framing rather than an independently built market model [This Week in Startups episode, February 2026]. Even using that company-stated ceiling conservatively, a business that captured 5 percent of that market would imply roughly $100 million in annual revenue (scenario, not a forecast). In software terms, that is enough to support a meaningful venture outcome if the company can prove durable retention and efficient acquisition. A more cautious public read is that the upside does not require winning all of healthcare. It requires becoming the category specialist that behavioral-health clinicians trust enough to let documentation expand into the rest of the administrative workflow [Digital Journal, December 2025] [Access Newswire, May 2026].
No independent source found -- This section relies materially on company statements, founder-reported metrics, and company-linked product pages, with limited independent corroboration beyond press coverage and accelerator participation.
Sources
Publicly reported
[Access Newswire, May 2026] Nextvisit AI Graduates from Jason Calacanis' LAUNCH Accelerator, Advances AI-Powered Clinical Documentation for Behavioral Health | https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nextvisit-ai-graduates-from-jason-calacanis-launch-accelerator-advanc-1119859
[Startuply.vc, May 2026] Nextvisit AI's $9,000 MRR Anchors a Bet on the Therapist's Scribe | https://startuply.vc/article/nextvisit-ai-s-9-000-mrr-anchors-a-bet-on-the-therapist-s-scribe-14dieg
[Digital Journal, December 2025] Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026 | https://www.digitaljournal.com/pr/news/pr-zen/nextvisit-co-founder-ryan-yannelli-identifies-1616928393.html
[This Week in Startups episode, February 2026] We built OpenClaw Ultron to replace 20 people at our company | https://pod.wave.co/podcast/this-week-in-startups/we-built-openclaw-ultron-to-replace-20-people-at-our-company-e2246
[USA Today, 2026] Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026 | https://www.usatoday.com/press-release/story/22086/nextvisit-co-founder-ryan-yannelli-identifies-six-critical-factors-for-behavioral-health-providers-evaluating-ai-scribes-in-2026/
[The News-Press, 2026] Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026 | https://www.news-press.com/press-release/story/17014/nextvisit-co-founder-ryan-yannelli-identifies-six-critical-factors-for-behavioral-health-providers-evaluating-ai-scribes-in-2026/
[LinkedIn, retrieved 2026] Faisal Rafiq MD. - CEO, Co-founder @ Nextvisit AI (LA35) | https://www.linkedin.com/in/faisal-rafiq-md/
[Crunchbase] Nextvisit AI - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/nextvisit
[ryanyannelli.com] Ryan Yannelli | Technologist, Founder, Advocate | https://ryanyannelli.com/
[nextvisit.ai, retrieved 2026] Careers | Nextvisit | https://nextvisit.ai/careers
Articles about Nextvisit AI
- Nextvisit AI Drafts SOAP Notes for 68 Behavioral Health Practices — The New York startup, co-founded by a psychiatrist, reports $9,000 in monthly revenue from clinicians using its specialized documentation tool.